
Please try another search
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging agents for use in immuno-oncology; and Carina Biotech Pty Ltd to develop CAR-T cell therapies for solid tumor. The company was incorporated in 2006 and is based in Camberwell, Australia.
Name | Age | Since | Title |
---|---|---|---|
Steve Felstead | 65 | - | Scientific Advisor |
Paul Donald Richard MacLeman | 59 | 2015 | Non-Executive Chairman |
Timothy Charles Oldham | - | 2019 | CEO, MD & Director |
David Everett Fuller | 61 | 2020 | Non-Executive Director |
Brian Richardson | - | - | Scientific Advisor |
John Westwick | - | - | Scientific Advisor |
Michelle Elizabeth Burke | - | 2024 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review